Results 221 to 230 of about 113,281 (294)
In 1,468 patients with type 2 diabetes, central obesity (WHtR >0.5) neutralizes the protective effects of higher BMI on muscle strength. Concurrently, visceral adiposity and CKD impose an additive threat, maximizing low handgrip strength risk (aOR = 1.74). Combining WHtR and renal tracking optimizes clinical sarcopenia screening.
Shing‐Hua Chen +4 more
wiley +1 more source
Among participants aged 40–75 years, sarcopenic obesity was observed in 4.9% of those with T2D and 0.5% of non‐D individuals. Sarcopenic obesity is more prevalent in individuals with T2D and is associated with impaired physical QOL, reduced walking ability, and increased falls.
Hiroyasu Mori +12 more
wiley +1 more source
Do Intoxicated Offenders Deserve Harsher Sentences? Questioning Veritas in Vino
ABSTRACT Criminal courts increasingly treat intoxication as an aggravating rather than a mitigating factor in sentencing. This shift, seen in Australian law and other jurisdictions, raises the prospect of unjust outcomes. We examine this trend through the lens of desert‐based justifications for punishment, setting aside questions of deterrence and ...
Mary Jean Walker, Daniel B. Cohen
wiley +1 more source
Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
ABSTRACT Introduction Increased risk of suicidality has been reported in association with glucagon‐like peptide receptor agonist (GLP‐1 RA) prescription. Herein, we conducted a comprehensive review evaluating reports of GLP‐1 RA prescription and suicidality.
Hezekiah C. T. Au +9 more
wiley +1 more source
Comparison of medication persistence and adherence in type 2 diabetes using a once-weekly regimen of DPP-4 inhibitor compared with once-daily and twice-daily regimens: a retrospective cohort study of Japanese health insurance claims data. [PDF]
Miwa T +4 more
europepmc +1 more source
Improvement of Glycemia by DPP-4 Inhibitors
Nishi, Y., Fujimoto, S.
openaire +1 more source
GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
ABSTRACT GLP‐1 receptor agonist medications have the potential to promote marked weight loss, but maximal and sustained benefit may be compromised by poor compliance and cessation of use. Development of next‐generation medications that address current obstacles to effective use and development of effective adjunct treatments will benefit from better ...
Giorgia Rutigliani +8 more
wiley +1 more source
DPP-4 inhibitor (sitagliptin)-induced seronegative rheumatoid arthritis. [PDF]
Padron S +3 more
europepmc +1 more source
Drug‐Induced Sialolithiasis—A Big‐Data Retrospective Study
ABSTRACT Background Sialolithiasis pathophysiology is multifactorial, with systemic medications often hypothesised as a key contributor, particularly in older adults (Drug‐Induced Sialolithiasis). However, robust evidence supporting this theory is limited.
Gal Avishai +5 more
wiley +1 more source
A catalytic network embedding a formal rearrangement enables the first catalytic enantioselective multicomponent reaction (MCR) of sulfur ylides. In the presence of a bulky chiral phosphoric acid, the reaction combines sulfoxonium ylides, aldehydes and thiols, and affords synthetically versatile β‐hydroxy‐α‐sulfanyl carbonyl compounds in ...
Nicolò Santarelli +10 more
wiley +2 more sources

